{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:39:34Z","timestamp":1790192374083,"version":"4.1.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T00:00:00Z","timestamp":1656288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T00:00:00Z","timestamp":1656288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Women's Health"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>In May 2018, following the preliminary results of a study in Botswana that reported congenital anomalies in babies born to HIV-positive women taking dolutegravir drug, the WHO issued a teratogenicity alert. However, there are scarce data on the impact of this guidance on contraceptive uptake among women taking dolutegravir. We assessed the uptake of contraceptives in HIV-positive women of reproductive age on dolutegravir regimens.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a cross-sectional survey from April 2019 to July 2019 in five government health facilities in central Uganda, where dolutegravir-based regimens were offered as the preferred first-line antiretroviral treatment. We randomly selected 359 non-pregnant women aged 15\u201349\u00a0years taking dolutegravir-based regimens and interviewed them using semi-structured interviewer-administered questionnaires. We collected data on demographics, contraceptive use, individual, social, and health system factors. We described patients\u2019 characteristics using descriptive statistics and assessed factors associated with contraceptive uptake using a modified Poisson regression model.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 359 women were included in the study. The mean age was 37\u00a0years (standard deviation\u2009=\u20096.8) and overall contraceptive uptake was 38.4%. The most utilized method was injectable method at 58.4% followed by condoms (15%), intrauterine device (10.7%), pills (6.4%), implants (5.4%), and sterilization (0.7%). Predictors for contraceptive uptake were parity of 3\u20134 children (Adjusted Prevalence Ratio (APR)\u2009=\u20091.48, 95% confidence interval (CI): 1.14, 1.92) in reference to those with 1\u20132 children. There was reduced contraceptive uptake in women of the age range 40\u201349\u00a0years (APR\u2009=\u20090.45, CI: 0.21\u20130.94) compared to those aged 15\u201324\u00a0years. Unemployed women were less likely to use contraceptives (APR: 0.6, CI: 0.42- 0.94) than the formally employed. Contraceptive uptake was lower among women who did not discuss family planning with their partners (APR\u2009=\u20090.39, CI: 0.29\u20130.52) than those who discussed family planning with their partners and women who did not receive family planning counseling (APR\u2009=\u20090.56, CI: 0.34\u20130.92) than those who received family planning counselling.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>We observed a low-level uptake of contraceptives, with injectables as the most used method. Family planning counseling and partner discussion on family planning were associated with contraceptive uptake among the women who used dolutegravir-based regimens. There is a need for more strategies to integrate FP services and increase male involvement in HIV care programs.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12905-022-01842-7","type":"journal-article","created":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T20:03:00Z","timestamp":1656360180000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Factors associated with uptake of contraceptives among HIV positive women on dolutegravir based anti-retroviral treatment-a cross sectional survey in urban Uganda"],"prefix":"10.1186","volume":"22","author":[{"given":"Leah","family":"Mbabazi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariah Sarah","family":"Nabaggala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Kiwanuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliet","family":"Kiguli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Laker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Kiconco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Okoboi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Lamorde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Castelnuovo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,27]]},"reference":[{"key":"1842_CR1","unstructured":"UNAIDS. Global HIV & AIDS statistics\u2014fact sheet. 2021, UNAIDS: Geneva, Switzerland."},{"key":"1842_CR2","unstructured":"MOH. Uganda population-based HIV impact assessment. 2018, Ministry of Health Uganda, ICAP Columbia University: Kampala."},{"key":"1842_CR3","doi-asserted-by":"crossref","unstructured":"Darroch JE, Sully E, Biddlecom A. adding it up: investing in contraception and maternal and newborn health, 2017. 2017, The Guttmacher Institute, United Nations Populations Fund (UNFPA): Washington DC and Newyork City.","DOI":"10.1363\/2018.29523"},{"issue":"1","key":"1842_CR4","doi-asserted-by":"publisher","first-page":"16319","DOI":"10.1038\/s41598-020-73490-6","volume":"10","author":"A Napyo","year":"2020","unstructured":"Napyo A, et al. Prevalence and predictors for unintended pregnancy among HIV-infected pregnant women in Lira, Northern Uganda: a cross-sectional study. Sci Rep. 2020;10(1):16319.","journal-title":"Sci Rep"},{"key":"1842_CR5","unstructured":"UBOS IA. Uganda demographic health survey 2016. 2018, Uganda Bureau of Statistics (UBOS): Kampala, Uganda and Rockville, Maryland, USA."},{"key":"1842_CR6","unstructured":"Avert. www.avert.org. In: Global Information and education on HIV and AIDS. 2018."},{"key":"1842_CR7","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/1471-2458-13-98","volume":"13","author":"RK Wanyenze","year":"2013","unstructured":"Wanyenze RK, et al. Fertility and contraceptive decision-making and support for HIV infected individuals: Client and provider experiences and perceptions at two HIV clinics in Uganda. BMC Public Health. 2013;13:98.","journal-title":"BMC Public Health"},{"key":"1842_CR8","unstructured":"Milanga M, Rutter L. Dolutegravir in Southern & Eastern Africa and the right to choose- policy briefing. 2018, HealthGAP: South Africa and Kenya. p. 2\u201316."},{"key":"1842_CR9","unstructured":"WHO. Statement on DTG. 2018, World Health Organisation (WHO): Geneva."},{"key":"1842_CR10","first-page":"528","volume":"6","author":"J Dorward","year":"2018","unstructured":"Dorward J, Hamers R. Dolutegravir in sub-Saharan Africa: context is crucial. Lancet HIV. 2018;6:528.","journal-title":"Lancet HIV"},{"key":"1842_CR11","unstructured":"WHO. Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV July 2018. 2018, World Health Organization (WHO): Geneva. p. 5."},{"issue":"10143","key":"1842_CR12","doi-asserted-by":"publisher","first-page":"3164","DOI":"10.1016\/S0140-6736(18)31641-6","volume":"392","author":"E Nakkazi","year":"2018","unstructured":"Nakkazi E. Changes to dolutegravir policy in several African countries. The Lancet. 2018;392(10143):3164\u20136.","journal-title":"The Lancet"},{"issue":"4","key":"1842_CR13","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/S1473-3099(20)30117-1","volume":"20","author":"L Chouchana","year":"2020","unstructured":"Chouchana L, et al. Dolutegravir and neural tube defects: a new insight. Lancet Infect Dis. 2020;20(4):405\u20136.","journal-title":"Lancet Infect Dis"},{"key":"1842_CR14","volume-title":"Survey sampling","author":"L Kish","year":"1965","unstructured":"Kish L. Survey sampling. New York: Wiley; 1965."},{"key":"1842_CR15","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1155\/2018\/9680514","volume":"2018","author":"F Bongomin","year":"2018","unstructured":"Bongomin F, et al. Prevalence and factors associated with contraceptive use among HIV-infected women of reproductive age attending infectious disease clinic at Gulu Regional Referral Hospital, Northern Uganda. Biomed Res Int. 2018;2018:8.","journal-title":"Biomed Res Int"},{"issue":"4","key":"1842_CR16","doi-asserted-by":"publisher","first-page":"e94682","DOI":"10.1371\/journal.pone.0094682","volume":"9","author":"A Melaku","year":"2014","unstructured":"Melaku A, Zeleke EG. Contraceptive utilization and associated factors among HIV positive women on chronic follow up care in Tigray Region, Northern Ethiopia: a cross sectional study. PLoS ONE. 2014;9(4):e94682.","journal-title":"PLoS ONE"},{"issue":"1","key":"1842_CR17","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1186\/s13104-017-2914-0","volume":"10","author":"R Tsegaye","year":"2017","unstructured":"Tsegaye R. Family planning need of people living with HIV\/AIDS in antiretroviral therapy clinics of Horro Guduru Wollega zone, Ethiopia. BMC Res Notes. 2017;10(1):581.","journal-title":"BMC Res Notes"},{"key":"1842_CR18","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/1472-6874-14-126","volume":"14","author":"D Laryea","year":"2014","unstructured":"Laryea D, et al. Contraceptive use and unmet need for family planning among HIV positive women on antiretroviral therapy in Kumasi, Ghana. BMC Womens Health. 2014;14:126.","journal-title":"BMC Womens Health"},{"issue":"6","key":"1842_CR19","first-page":"355","volume":"4","author":"G Abebe","year":"2011","unstructured":"Abebe G, Nigatu R. Family planning service utilization in Mojo town, Ethiopia: a population based study. J Geogr Reg Plan. 2011;4(6):355\u201363.","journal-title":"J Geogr Reg Plan"},{"issue":"7","key":"1842_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0040670","volume":"7","author":"KM Elfstrom","year":"2012","unstructured":"Elfstrom KM, Stephenson R. The role of place in shaping contraceptive use among women in Africa. PLoS ONE. 2012;7(7): e40670.","journal-title":"PLoS ONE"},{"issue":"6","key":"1842_CR21","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.2105\/AJPH.2010.300091","volume":"101","author":"D Shattuck","year":"2011","unstructured":"Shattuck D, et al. Encouraging contraceptive uptake by motivating men to communicate about family planning: the Malawi Male Motivator Project. Am J Public Health. 2011;101(6):1089\u201395.","journal-title":"Am J Public Health"},{"issue":"1","key":"1842_CR22","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s12905-018-0660-7","volume":"18","author":"EE Edietah","year":"2018","unstructured":"Edietah EE, et al. Contraceptive use and determinants of unmet need for family planning; a cross sectional survey in the North West Region, Cameroon. BMC Womens Health. 2018;18(1):171\u2013171.","journal-title":"BMC Womens Health"},{"issue":"4","key":"1842_CR23","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1363\/intsexrephea.41.4.0191","volume":"41","author":"A Gueye","year":"2015","unstructured":"Gueye A, et al. Belief in family planning myths at the individual and community levels and modern contraceptive use in Urban Africa. Int Perspect Sex Reprod Health. 2015;41(4):191\u20139.","journal-title":"Int Perspect Sex Reprod Health"}],"container-title":["BMC Women's Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-022-01842-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12905-022-01842-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-022-01842-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T20:26:50Z","timestamp":1700771210000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcwomenshealth.biomedcentral.com\/articles\/10.1186\/s12905-022-01842-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,27]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1842"],"URL":"https:\/\/doi.org\/10.1186\/s12905-022-01842-7","relation":{},"ISSN":["1472-6874"],"issn-type":[{"value":"1472-6874","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,27]]},"assertion":[{"value":"24 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by Makerere University Institute of Public Health Higher Degrees Research and Ethics Committee (HDREC), number 2016\/HD07\/2321U and Uganda National Council of Science and Technology (UNCST) number HS406ES. Written informed consent was obtained from each participant before any study activity and assent was obtained from the participants below 18\u00a0years of age. We also obtained written informed consent from parents or legal representatives of the minors. This study was carried out in accordance to the applicable ethical guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"This does not apply to this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"262"}}